In The News

Bodysphere EUA Blunder is a Lesson in What Not To Do

Medtech Insight

02 Apr 2020

Bethany Hills spoke to Medtech Insight for its coverage of Bodysphere’s retracted announcement of its emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a COVID-19 serologic test, which Bethany says should serve as a cautionary tale to other medtech companies.

“Do not release any press releases until you have the EUA letter in hand,” Bethany said. “The second you have it you can release every press release you want, and the FDA will put up the announcement on their website in a few hours.”

Read the full article (subscription required).

Close
Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.